



(51) International Patent Classification:

A61K 39/00 (2006.01) A61K 9/00 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2021/052890

(22) International Filing Date:

07 April 2021 (07.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/007,118 08 April 2020 (08.04.2020) US
63/026,387 18 May 2020 (18.05.2020) US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventors: VAN KOLEN, Kristof; Turnhoutseweg 30,
2340 Beerse (BE). MERCKEN, Marc; Turnhoutseweg 30,
2340 Beerse (BE). NANJUNDA, Rupesh; 1400 McKean
Road, Spring House, Pennsylvania 19477 (US). SINGH,
Sanjaya; 1400 McKean Road, Spring House, Pennsylva-

nia 19477 (US). LA PORTE, Sherry; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). LUO, Jinquan;
1400 McKean Road, Spring House, Pennsylvania 19477
(US). JAIPRASART, Pharavee; 1400 McKean Rd.,
Spring House, Pennsylvania 19477 (US). VENKATARA-
MANI, Sathyadevi; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US).

(74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, New Jer-
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANTI-PHF-TAU ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*